0001355250-11-000028.txt : 20111108 0001355250-11-000028.hdr.sgml : 20111108 20111108165239 ACCESSION NUMBER: 0001355250-11-000028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111107 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20111108 DATE AS OF CHANGE: 20111108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellceutix CORP CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134303398 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52321 FILM NUMBER: 111188380 BUSINESS ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: (978)-633-3623 MAIL ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 8-K 1 form8k.htm form8k.htm
 
 
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:  November 8,  2011
(Date of earliest event reported: November 3, 2011)

CELLCEUTIX CORPORATION
 
 
     
Nevada
  
30-0565645
     
(State or Other Jurisdiction of
  
(I.R.S. Employer
Incorporation or Organization)
  
Identification Number)
 

100 Cumming Center, Suite 151-B
Beverly, MA  01915

 
 (Address of principal executive offices and zip code)

(978)-633-3623
(Registrant's telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 


 
 
Item 3.02 Unregistered Sales of Equity Securities
 
 
 
On November 3, 2011, in connection with an offering by the Company of a maximum of up to 2,500,000 shares at $0.40   per share (the “Offering”), a "Subscriber"  Huang Min Chung,   subscribed  for 832,500  shares of the Company's Class A common stock upon payment of  $333,000. Subscriber is also entitled to one Stock Purchase Warrant exercisable at $1.00 for each share of Common Stock subscribed.   In connection with the issuance of   these shares, we relied upon the exemption from the registration provisions of the Act contained in Section 4(2) thereof
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  November 8, 2011
         
 
CELLCEUTIX CORPORATION
  
     
     
 
By:  
/s/ Leo Ehrlich
  
   
Chief Executive Officer